Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) SVP Sells 2,098 Shares of Stock
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva sold 2,098 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $163.08, for a total transaction of $342,141.84. Following the completion of the transaction, the senior vice president now directly owns 17,923 shares in the company, valued at approximately $2,922,882.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down $3.60 during mid-day trading on Wednesday, hitting $155.67. 1,812,036 shares of the company were exchanged, compared to its average volume of 1,880,000. Vertex Pharmaceuticals Incorporated has a 1 year low of $84.39 and a 1 year high of $174.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.58 and a current ratio of 4.79. The stock has a market capitalization of $39,370.00, a price-to-earnings ratio of 79.83, a PEG ratio of 2.26 and a beta of 1.61.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The firm had revenue of $651.63 million during the quarter, compared to analyst estimates of $592.49 million. During the same period last year, the firm posted $0.35 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 42.1% compared to the same quarter last year. research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.63 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of VRTX. Jennison Associates LLC grew its holdings in shares of Vertex Pharmaceuticals by 19.0% in the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after purchasing an additional 962,644 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Vertex Pharmaceuticals by 8,061.1% in the third quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock valued at $138,239,000 after purchasing an additional 898,089 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Vertex Pharmaceuticals by 9,422.3% in the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after purchasing an additional 883,998 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Vertex Pharmaceuticals by 1,191.3% in the second quarter. Janus Henderson Group PLC now owns 448,975 shares of the pharmaceutical company’s stock valued at $57,860,000 after purchasing an additional 414,206 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in shares of Vertex Pharmaceuticals by 88.1% in the second quarter. Lord Abbett & CO. LLC now owns 459,059 shares of the pharmaceutical company’s stock valued at $59,159,000 after purchasing an additional 215,062 shares in the last quarter. 92.81% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on VRTX shares. Maxim Group reissued a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Deutsche Bank assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They set a “buy” rating and a $175.00 target price on the stock. Royal Bank of Canada restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Oppenheimer raised their target price on shares of Vertex Pharmaceuticals from $175.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, January 4th. Finally, Bank of America restated a “buy” rating and set a $180.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $180.07.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-svp-sells-2098-shares-of-stock/1851132.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.